Fibrosis Mediators in the Colonic Mucosa of Acute and Healed Ulcerative Colitis

Clin Transl Gastroenterol. 2019 Oct;10(10):e00082. doi: 10.14309/ctg.0000000000000082.

Abstract

Objectives: A healed intestinal mucosa is the aim of therapy in acute ulcerative colitis (UC). Disruption of mucosal wound healing may lead to severe complications including intestinal fibrosis. This study examined mucosal gene expression in the healing process of acute UC with a special focus on known mediators of fibrosis.

Methods: Endoscopic biopsies from patients with acute, moderate to severe UC were analyzed with a quantitative polymerase chain reaction array for 84 genes involved in fibrosis pathways. All patients were treated with infliximab (anti- tumor necrosis factor). Biopsies were taken before therapy and when disease remission was reached, defined as a Mayo score of ≤2, with an endoscopic subscore of 0 or 1. A healthy control group was included. Immunostaining of matrix metallopeptidase 9 and smooth muscle actin was performed.

Results: Mucosal biopsies from acute UC (n = 28), remission UC (n = 28), and healthy controls (n = 13) were analyzed. Fibrosis and extracellular matrix-associated genes were upregulated in the endoscopically healed UC mucosa vs controls, with collagen type III alpha 1 chain, actin alpha 2, lysyl oxidase, TIMP metallopeptidase inhibitor 3, and caveolin 1 uniquely showing no overlap with acute disease. Pro- and antifibrotic mediators (interleukin [IL]13 receptor subunit alpha 2, IL1B, IL10, tumor necrosis factor, snail family transcriptional repressor 1, and C-C motif chemokine ligand 2) were upregulated in both acute and healed UC compared with controls. An attenuated pattern of the canonical transforming growth factor beta (TGFB) pathway was observed in acute UC and to a lesser extent in the healed mucosa, except for TGFB2, which was enhanced.

Discussion: The endoscopically healed mucosa of UC showed a persisting dysregulation of fibrosis-associated mediators compared with controls, including extracellular matrix remodeling, profibrotic cytokines, and TGFB signaling pathways.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Biopsy
  • Case-Control Studies
  • Colitis, Ulcerative / diagnosis
  • Colitis, Ulcerative / drug therapy*
  • Colitis, Ulcerative / immunology
  • Colitis, Ulcerative / pathology
  • Colon / diagnostic imaging
  • Colon / pathology*
  • Colonoscopy
  • Cytokines / metabolism
  • Extracellular Matrix / metabolism
  • Female
  • Fibrosis
  • Gastrointestinal Agents / pharmacology*
  • Gastrointestinal Agents / therapeutic use
  • Gene Expression Profiling
  • Humans
  • Infliximab / pharmacology
  • Infliximab / therapeutic use
  • Intestinal Mucosa / diagnostic imaging
  • Intestinal Mucosa / pathology*
  • Male
  • Middle Aged
  • Severity of Illness Index
  • Signal Transduction / physiology
  • Transforming Growth Factor beta / metabolism
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / immunology
  • Wound Healing / drug effects*
  • Wound Healing / immunology
  • Young Adult

Substances

  • Cytokines
  • Gastrointestinal Agents
  • TNF protein, human
  • Transforming Growth Factor beta
  • Tumor Necrosis Factor-alpha
  • Infliximab